학술논문
An anti–CD22-seco-CBI-dimer antibody–drug conjugate (ADC) for the treatment of non-hodgkin lymphoma that provides a longer duration of response than auristatin-based ADCs in preclinical models
Document Type
Article
Author
Source
In: Molecular Cancer Therapeutics . (Molecular Cancer Therapeutics, 1 February 2021, 20(2):340-346)
Subject
Language
English
ISSN
15388514
15357163
15357163